Puromycin aminonucleoside

Catalog No.S9631 Synonyms: NSC 3056, PAN, Stylomycin aminonucleoside, ARDMA, SAN

For research use only.

Puromycin aminonucleoside (NSC 3056, PAN, Stylomycin aminonucleoside, ARDMA, SAN), the aminonucleoside portion of the antibiotic puromycin, is a reversible inhibitor of dipeptidyl-peptidase II and cytosol alanyl aminopeptidase that induces apoptosis in mesangial cells (MCs) accompanied by declined cell viability and enhanced inflammatory response.

Puromycin aminonucleoside Chemical Structure

CAS No. 58-60-6

Purity & Quality Control

Choose Selective DPP-2 Inhibitors

Biological Activity

Description Puromycin aminonucleoside (NSC 3056, PAN, Stylomycin aminonucleoside, ARDMA, SAN), the aminonucleoside portion of the antibiotic puromycin, is a reversible inhibitor of dipeptidyl-peptidase II and cytosol alanyl aminopeptidase that induces apoptosis in mesangial cells (MCs) accompanied by declined cell viability and enhanced inflammatory response.
Targets
dipeptidyl-peptidase II [1]
()
cytosol alanyl aminopeptidase [1]
()
In vitro

Puromycin aminonucleoside (PAN) induces MC apoptosis accompanied by the declined cell viability and enhanced inflammatory response. In PAN-treated MCs, ERRα overexpression further aggravates PAN-induced apoptosis.[1]

In vivo

In agreement with the in vitro study, increased ERRα expression is observed in line with enhanced apoptotic response in renal cortex from PAN-treated rats.[1]

Protocol (from reference)

Cell Research:

[1]

  • Cell lines: mouse mesangial cells
  • Concentrations: 50 μg/ml, 100 μg/ml
  • Incubation Time: 24 h
  • Method:

    For apoptosis assay, mesangial cells are treated with PAN for 24 h at the indicated concentration. After treatment, cells are stained with FITC-Annexin V and PI according to the manufacturer’s protocol. Cell apoptosis is determined using a BD FACS Calibur flow cytometer and data is analyzed with Flowjo software.

  • (Only for Reference)
Animal Research:

[1]

  • Animal Models: male Sprague-Dawley rats
  • Dosages: 150 mg/kg
  • Administration: IV
  • (Only for Reference)

Solubility (25°C)

In vitro

DMSO 59 mg/mL
(200.46 mM)
Water 30 mg/mL
(101.93 mM)
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 294.31
Formula

C12H18N6O3

CAS No. 58-60-6
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CN(C)C1=NC=NC2=C1N=CN2C3C(C(C(O3)CO)N)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05093231 Not yet recruiting Drug: Pembrolizumab|Drug: Olaparib Pancreatic Cancer Cambridge University Hospitals NHS Foundation Trust|National Institute for Health Research United Kingdom March 3 2022 Phase 2
NCT05167825 Not yet recruiting Drug: Macitentan Pulmonary Arterial Hypertension Janssen Pharmaceutical K.K. March 31 2022 Phase 3
NCT05176210 Not yet recruiting Drug: PS1|Drug: Placebo Type II Diabetes Pharmasaga Co. Ltd. February 2022 Phase 1
NCT05139199 Not yet recruiting Behavioral: Auricular Point Acupressure group Pancreatic Cancer Taipei Veterans General Hospital Taiwan December 10 2021 Not Applicable

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Puromycin aminonucleoside | Puromycin aminonucleoside supplier | purchase Puromycin aminonucleoside | Puromycin aminonucleoside cost | Puromycin aminonucleoside manufacturer | order Puromycin aminonucleoside | Puromycin aminonucleoside distributor